...
【24h】

Renoprotective effect of rosuvastatin in DOCA-salt hypertensive rats.

机译:瑞舒伐他汀对DOCA盐高血压大鼠的肾脏保护作用。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Pleiotropic effects of statins represent potential mechanisms for the treatment of end organ damage in hypertension. This study has investigated the effects of rosuvastatin (10 mg/kg/day) on renal function impairment, glomerulosclerosis and tubulointerstitial fibrosis in deoxycorticosterone acetate (DOCA)-salt hypertensive (DSH) rat. METHODS: Rats were implanted with DOCA strips (200 mg/kg) on 1 week after unilateral nephrectomy. Rats received a controlled diet with or without rosuvastatin. Three weeks after DOCA implantation, systolic blood pressure (SBP) was measured by tail-cuff method. The glomerulosclerosis and tubulointerstitial fibrosis was determined by Masson's trichrome stain. The tumour necrosis factor (TNF-alpha), interleukin-1beta (IL-1beta), interferon-gamma (IFN-gamma), monocyte chemoattractant protein1 (MCP1), intercellular adhesion molecule-1 (ICAM-1) and endothelin-1 (ET-1) were determined by real-time polymerase chain reaction. The expression of ED-1, transforming growth factor-beta1 (TGF-beta1) and connective tissue growth factor (CTGF) was determined in the kidney by immunoblotting and immunohistochemistry. RESULTS: In DSH rats, SBP was increased, which was not affected by rosuvastatin treatment. Creatinine clearance was decreased while urinary albumin excretion ratio was increased in DSH rats compared with controls, which were attenuated by rosuvastatin treatment. Glomerulosclerosis and tubulointerstitial fibrosis in DSH rats were attenuated by rosuvastatin treatment. The messenger RNA expression of TNF-alpha, IL-1beta, IFN-gamma, MCP1, ICAM-1 and ET-1 was increased in DSH, which was attenuated by rosuvastatin treatment. The expression of ED-1, TGF-beta and CTGF was increased in the kidney of DSH, which was counteracted by rosuvastatin treatment. CONCLUSION: Rosuvastatin is effective in preventing progression of renal injury in DSH, the mechanism of which is associated with anti-inflammatory and anti-fibrotic effects.
机译:背景:他汀类药物的多效性代表了治疗高血压终末器官损害的潜在机制。这项研究已经研究了瑞舒伐他汀(10 mg / kg /天)对醋酸脱氧皮质酮(DOCA)-盐高血压(DSH)大鼠肾功能损害,肾小球硬化和肾小管间质纤维化的影响。方法:单侧肾切除术后1周,将DOCA条(200 mg / kg)植入大鼠体内。大鼠接受或不接受瑞舒伐他汀的控制饮食。 DOCA植入后三周,通过尾袖法测量收缩压(SBP)。肾小球硬化和肾小管间质纤维化是由马森氏三色染色确定的。肿瘤坏死因子(TNF-alpha),白介素1beta(IL-1beta),干扰素-γ(IFN-γ),单核细胞趋化蛋白1(MCP1),细胞间粘附分子1(ICAM-1)和内皮素1( ET-1)通过实时聚合酶链反应确定。通过免疫印迹和免疫组织化学测定肾脏中ED-1,转化生长因子-beta1(TGF-beta1)和结缔组织生长因子(CTGF)的表达。结果:在DSH大鼠中,SBP增加,不受瑞舒伐他汀治疗影响。与对照组相比,DSH大鼠的肌酐清除率降低,尿白蛋白排泄率升高,而瑞舒伐他汀治疗则减弱了肌酐清除率。瑞舒伐他汀治疗可减轻DSH大鼠的肾小球硬化和肾小管间质纤维化。在DSH中,TNF-α,IL-1β,IFN-γ,MCP1,ICAM-1和ET-1的信使RNA表达增加,这被瑞舒伐他汀处理所减弱。瑞舒伐他汀治疗可抵消DSH肾脏中ED-1,TGF-β和CTGF的表达。结论:瑞舒伐他汀可有效预防DSH肾损伤的进展,其机制与抗炎和抗纤维化作用有关。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号